Meeting
2017 ASCO Annual Meeting
A first-in-human first-in-class (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours.
Authors
Sarah E. R. Halford
Cancer Research UK Centre for Drug Development, London, United Kingdom
Sarah E. R. Halford , Paul Jones , Steve Wedge , Sandra Hirschberg , Sidath Katugampola , Gareth Veal , Geoffrey Payne , Chris Bacon , Sarah Potter , Melanie Griffin , Maxime Chenard-Poirier , George Petrides , Graham Holder , Hector C Keun , Udai Banerji , Elizabeth R. Plummer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT01791595
Citation
J Clin Oncol 35, 2017 (suppl; abstr 2516)
DOI
10.1200/JCO.2017.35.15_suppl.2516
Abstract #
2516
Poster Bd #
8
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase I study of nelmastobart (hSTC810), an anti-BTN1A1 antibody, in patients with advanced solid tumors.
First Author: Soohyeon Lee
Poster
2020 ASCO Virtual Scientific Program
Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid tumors.
First Author: Jasmine Huynh
Poster
2019 ASCO Annual Meeting
A phase I study of pazopanib with weekly paclitaxel and carboplatin in advanced solid tumors.
First Author: Nancy Chan
Poster
2019 ASCO Annual Meeting
Phase I study of the Aurora A kinase (AurA) inhibitor TAS-119 with paclitaxel (P) in advanced solid tumors.
First Author: Dana Backlund Cardin